CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
City of Hope Medical Center
Eli Lilly and Company
Kivu Bioscience Inc.
Exelixis
Mersana Therapeutics
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Novartis
Exscientia AI Limited
Royal Marsden NHS Foundation Trust
Epsilogen Ltd
Calibr, a division of Scripps Research
Zumutor Biologics Inc.
H. Lee Moffitt Cancer Center and Research Institute
Arcus Biosciences, Inc.
IDEAYA Biosciences
Sotio Biotech Inc.
SillaJen, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
Rondo Therapeutics
Bayer
Mabwell (Shanghai) Bioscience Co., Ltd.
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
BioNTech SE
Novartis
NiKang Therapeutics, Inc.
Rush University Medical Center
Alterome Therapeutics, Inc.
BeOne Medicines
Aktis Oncology, Inc.
OncoTherapy Science, Inc.
Radiopharm Theranostics, Ltd
Accent Therapeutics
Seagen Inc.
ProteinQure Inc.
IntoCell, Inc
Tizona Therapeutics, Inc
Washington University School of Medicine
Normunity AccelCo, Inc.
NiKang Therapeutics, Inc.